Hierarchy of risk based on history and location of prior myocardial infarction in the thrombolytic era

American Heart Journal

Volumn 140, Issue 1, 2000, Pages 29-33

  Brieger, David B ^a   Mak, Koon Hou ^b   Miller, David P ^c   Califf, Robert M ^d   Topol, Eric J ^e  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b DEPARTMENT OF CARDIOLOGY   (Singapore)

^c Technology Assessment Group   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANAMNESIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; ST SEGMENT ELEVATION;

EID: 0033943358     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2000.106166     Document Type: Article

References (11)

1. Brieger DB, Mak KH, White HD, et al, for the GUSTO I Investigators. The benefit of early sustained reperfusion in patients with acute myocardial infarction superimposed on prior infarction: insights from the GUSTO-1 Trial. Am J Cardiol 1998;81:282-7.
2. Lee KL, Woodlief L, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for myocardial infarction: results from an international trial of 41,021patients. Circulation 1995;91:1659-68.
3. Moshkovitz Y, Scarovsky S, Behar S, et al, and the SPRINT Study Group. Infarct site-related mortality in patients with recurrent myocardial infarction. Am J Med 1993;94:388-94.
4. Kornowski R, Chetrit A, Barbash G, for the Israeli Investigators. Prognostic importance of previous myocardial infarction in patients receiving thrombolytic therapy for acute infarction. J Thromb Thrombolysis 1996;3:391-5.
5. GUSTO Investigators. An international randomized trial comparing 4 thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
6. Fibrinolytic Therapy Trialists' Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994;343:311-22.
7. Stone PH, Raabe DS, Jaffe AS, et al, for the MILIS Group. Prognostic significance of location and type of myocardial infarction: independent adverse outcome associated with anterior location. J Am Coll Cardiol 1988;11:453-63.
8. Hands ME, Lloyd BL, Robinson JS, et al. Prognostic significance of electrocardiographic site of infarction after correction for enzymatic size of infarction. Circulation 1986;73:885-91.
9. Vaccarino V, Krumholz HM, Berkman LF, et al. Sex differences in mortality after myocardial infarction. Circulation 1995;91:1861-71.
10. Kleiman NS, White HD, Ohman M, et al, for the GUSTO Investigators. Mortality within 24 hours of thrombolysis for myocardial infarction: the importance of early reperfusion. Circulation 1994;90:2658-65.
11. Mueller HS, Cohen LS, Braunwald E, et al, for the TIMI Investigators. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction: analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase II. Circulation 1992;85:1254-64.